Search Results - "Kadia, T"

Refine Results
  1. 1

    New drugs in acute myeloid leukemia by Kadia, T.M., Ravandi, F., Cortes, J., Kantarjian, H.

    Published in Annals of oncology (01-05-2016)
    “…The standard therapy for acute myeloid leukemia (AML) has not changed meaningfully for the past four decades. Improvements in supportive care and modifications…”
    Get full text
    Journal Article
  2. 2
  3. 3

    BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells by Saenz, D T, Fiskus, W, Manshouri, T, Rajapakshe, K, Krieger, S, Sun, B, Mill, C P, DiNardo, C, Pemmaraju, N, Kadia, T, Parmar, S, Sharma, S, Coarfa, C, Qiu, P, Verstovsek, S, Bhalla, K N

    Published in Leukemia (01-03-2017)
    “…Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription…”
    Get full text
    Journal Article
  4. 4
  5. 5

    A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome by Daver, N, Kantarjian, H, Ravandi, F, Estey, E, Wang, X, Garcia-Manero, G, Jabbour, E, Konopleva, M, O'Brien, S, Verstovsek, S, Kadia, T, Dinardo, C, Pierce, S, Huang, X, Pemmaraju, N, Diaz-Pines-Mateo, M, Cortes, J, Borthakur, G

    Published in Leukemia (01-02-2016)
    “…Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110…”
    Get full text
    Journal Article
  6. 6

    Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) by Jain, P., Aoki, E., Keating, M., Wierda, W.G., O’Brien, S., Gonzalez, G.N., Ferrajoli, A., Jain, N., Thompson, P.A., Jabbour, E., Kanagal-Shamanna, R., Pierce, S., Alousi, A., Hosing, C., Khouri, I., Estrov, Z., Cortes, J., Kantarjian, H., Ravandi, F., Kadia, T.M.

    Published in Annals of oncology (01-07-2017)
    “…T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive disease. In this study, we report our experience from 119 patients with T-PLL. We reviewed the…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation by Chen, Y, Kantarjian, H, Pierce, S, Faderl, S, O'Brien, S, Qiao, W, Abruzzo, L, de Lima, M, Kebriaei, P, Jabbour, E, Daver, N, Kadia, T, Estrov, Z, Garcia-Manero, G, Cortes, J, Ravandi, F

    Published in Leukemia (01-04-2013)
    “…The clinical features and outcomes of 148 patients with acute myeloid leukemia (AML) and 11q23 chromosomal abnormalities were compared with those of 2640…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13

    Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL by Khouri, I F, Sui, D, Jabbour, E J, Samuels, B I, Turturro, F, Alatrash, G, Anderlini, P, Ahmed, S, Oran, B, Ciurea, S O, Marin, D, Olson, A, Patel, K K, Popat, U R, Ledesma, C, Kadia, T M, Ferrajoli, A, Burger, J A, Jorgensen, J L, Medeiros, L J, Bassett, R L, Gulbis, A M

    Published in Bone marrow transplantation (Basingstoke) (01-01-2017)
    “…Bendamustine has shown a favorable safety profile when included in chemotherapy regimens for several types of lymphoma, including CLL. This study investigated…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20